美国大型生物制药企业：本土制造体系建设下，潜在 100% 关税大概率可规避-US Large Cap BioPharma Potential 100% Tariff Should Largely Be Avoidable With US Based Manufacturing Buildout
2025-09-26 02:32
Potential 100% Tariff Should Largely Be Avoidable With US Based Manufacturing Buildout J P M O R G A N North America Equity Research 25 September 2025 US Large Cap BioPharma Today, President Trump announced that branded / patented pharma products will be subject to a 100% tariff, effective October 1, unless a company is building their mfg. plant in America (defined as breaking ground / under construction). Overall, while there remains very limited details, we note that this will likely lead to a majority of ...